Peptide Database

A small molecule NNMT inhibitor studied for metabolic effects. May enhance energy expenditure and reduce fat accumulation through NAD+ pathway modulation.

A discontinued ActRIIB-Fc fusion protein that acted as a myostatin trap. Development halted in 2011 due to bleeding-related safety concerns.

A cell-permeable AMPK activator that mimics metabolic effects of exercise. Studied as an "exercise pill" but banned by WADA as a metabolic modulator.

A modified fragment of human growth hormone designed to isolate fat-burning effects without growth promotion. Completed Phase 2 clinical trials for obesity but was not approved.

An EPO-derived peptide that provides tissue protection and neuroprotection without blood cell stimulation. Activates the innate repair receptor.

A cosmetic peptide that reduces expression lines by inhibiting neuromuscular transmission. Known as a topical Botox alternative for anti-aging skincare.

A synthetic 15-amino acid peptide derived from human gastric juice protein, extensively studied for tissue healing, gastrointestinal protection, and regenerative properties. One of the most researched peptides in regenerative medicine.

A tetrapeptide that selectively binds to injured brain tissue by targeting tenascin-C and proteoglycan complexes upregulated at injury sites. CAQK shows significant neuroprotective effects and is being developed as a potential first-in-class treatment for traumatic brain injury.

A Khavinson bioregulator tetrapeptide for cardiac support. Targets heart muscle function and myocardial health.

A neuropeptide mixture from porcine brain containing BDNF, NGF, and other neurotrophic factors, approved in Europe/Asia for stroke and dementia.

A synthetic GHRH analog with extended half-life, designed to stimulate growth hormone production. Available in DAC (long-acting) and no DAC forms. Often combined with GHRPs for synergistic effects.

A modified GHRH analog with extended half-life (6-8 days) through albumin binding, providing sustained growth hormone elevation with once-weekly dosing.

A Khavinson tetrapeptide bioregulator for cerebral cortex, promoting neuroprotection and neural repair.

A cosmetic peptide for skin lightening through tyrosinase inhibition. Used for hyperpigmentation, dark spots, and skin brightening without hydroquinone risks.

An extremely potent nootropic peptide derived from angiotensin IV. Works through HGF/c-Met signaling with reported effects millions of times more potent than BDNF.

A neuropeptide that promotes delta wave sleep and modulates stress responses. Research shows effects on sleep quality, stress adaptation, and hormone regulation.

An FDA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes with demonstrated cardiovascular benefits in the REWIND trial.

Elamipretide is a synthetic mitochondria-targeting tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane. FDA-approved in 2025 for Barth syndrome, it stabilizes mitochondrial cristae structure, reduces oxidative stress, and enhances ATP production.

A synthetic tetrapeptide based on the pineal gland peptide epithalamin, studied for its effects on telomerase activation and anti-aging properties. Developed by Russian researcher Vladimir Khavinson.

The first FDA-approved GLP-1 agonist (2005), derived from Gila monster venom, pioneering the incretin mimetic drug class for type 2 diabetes.

A myostatin-inhibiting glycoprotein that removes the natural limit on muscle growth. Studied for muscle wasting diseases, muscular dystrophy, and age-related muscle loss.

A senolytic peptide that selectively induces death in senescent cells by disrupting the FOXO4-p53 interaction. Represents a novel approach to targeting cellular aging.

A peptide fragment of human growth hormone containing the lipolytic region. Studied for fat-burning effects without the growth-promoting properties of full GH.

A TGF-β family member studied as a potential rejuvenation factor, though research remains controversial.

A naturally occurring tripeptide that modulates over 4,000 genes, promoting wound healing, collagen synthesis, and tissue regeneration.

A naturally occurring copper-bound tripeptide with powerful effects on wound healing, collagen synthesis, and skin regeneration. Declines with age and is widely used in both cosmetic and research applications.

One of the most potent growth hormone releasing peptides, GHRP-2 provides strong GH stimulation with moderate appetite effects. Often combined with GHRH analogs for synergistic effects.

One of the first synthetic growth hormone secretagogues, GHRP-6 activates the ghrelin receptor to stimulate robust GH release. Known for significant appetite stimulation due to ghrelin pathway activation.

Synthetic GnRH identical to the natural hormone. FDA-approved for diagnostic testing and fertility treatment. Stimulates LH and FSH release from the pituitary.

The most potent GHRP for growth hormone release, hexarelin also exhibits unique cardioprotective properties. More prone to desensitization than other GHRPs.

Human Growth Hormone (HGH), also known as somatropin, is a 191-amino acid peptide hormone naturally produced by the pituitary gland. It plays a critical role in growth, metabolism, cell regeneration, and body composition. Recombinant HGH is FDA-approved for multiple medical conditions and serves as the foundation for understanding growth hormone-related peptide research.

The first discovered mitochondrial-derived peptide, humanin provides broad cytoprotective effects against cell death. Studied for neuroprotection in Alzheimer's and metabolic disease.

A modified form of IGF-1 with enhanced potency and extended half-life. Modifications prevent binding protein sequestration, increasing bioavailability approximately 2-3 fold.

A highly selective growth hormone releasing peptide (GHRP) that stimulates GH release with minimal impact on cortisol and prolactin. Known for its clean side effect profile and synergy with GHRH analogs.

The minimal active fragment of kisspeptin that regulates the reproductive axis. Stimulates GnRH release to control fertility and puberty.

An anti-inflammatory tripeptide from α-MSH that inhibits NF-κB signaling. Studied for inflammatory bowel disease and gut inflammation without tanning effects.

An enkephalin-mimetic cosmetic peptide that promotes muscle relaxation to reduce expression lines. Works through opioid-like receptor activation.

An FDA-approved GnRH agonist used for prostate cancer, endometriosis, and precocious puberty through pituitary desensitization and hormone suppression.

An FDA-approved GLP-1 agonist for type 2 diabetes and weight management. Requires daily dosing. The first GLP-1 approved specifically for obesity treatment.

The only human cathelicidin antimicrobial peptide, LL-37 provides broad-spectrum antimicrobial activity and immunomodulatory effects. Key component of innate immunity.

Shorter fragments of the full LL-37 antimicrobial peptide that retain biological activity. Easier to synthesize while maintaining antimicrobial and immunomodulatory effects.

An FDA-approved oral ghrelin agonist for diagnosing adult growth hormone deficiency.

A dual-peptide complex combining collagen-stimulating and anti-inflammatory peptides. One of the most researched anti-aging ingredients in cosmetics.

An FDA-approved selective MC1R agonist for erythropoietic protoporphyria. Provides UV-free tanning and photoprotection without the sexual side effects of Melanotan II.

A synthetic melanocortin receptor agonist known for tanning and sexual function effects. Not FDA approved and carries significant safety concerns including potential melanoma risk.

A splice variant of IGF-1 produced in response to muscle damage. Activates satellite cells to initiate muscle repair. First signal in the muscle regeneration cascade.

A potent, orally active growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release without affecting cortisol levels.

A mitochondrial-derived peptide that regulates metabolism through AMPK activation. Studied as an exercise mimetic with effects on insulin sensitivity, fat oxidation, and longevity.

An enhanced anxiolytic peptide analog of tuftsin with superior stability, providing GABA modulation and anxiety relief without benzodiazepine-like side effects.

An enhanced nootropic peptide derived from ACTH(4-10) with superior stability and bioavailability, promoting BDNF expression and cognitive enhancement.

An essential coenzyme that declines with age. Critical for energy metabolism, DNA repair, and sirtuin activation. Target for longevity research.

A skin-lightening peptide that blocks α-MSH at MC1R receptors to reduce melanin production. Works at the receptor level rather than enzyme inhibition.

An FDA-approved somatostatin analog for acromegaly and neuroendocrine tumors, inhibiting growth hormone and various gut hormones.

A 33-amino acid neuropeptide critical for regulating wakefulness, with deficiency causing narcolepsy type 1.

The "love hormone" involved in social bonding, reproduction, and maternal behavior. FDA-approved for labor induction and postpartum hemorrhage. Researched for social and psychiatric applications.

A synthetic CNTF-derived peptide that promotes neurogenesis and BDNF release. Designed for blood-brain barrier penetration and cognitive enhancement research.

An anti-inflammatory cosmetic peptide that reduces IL-6 production. Component of Matrixyl 3000 complex for anti-aging applications.

A Khavinson bioregulator tetrapeptide targeting pancreatic function. Studied for effects on insulin regulation and glucose metabolism.

A neurotrophic peptide derived from prosaposin that activates GPR37 receptors. Studied for neuroprotection and cognitive enhancement.

A PEGylated version of MGF with extended half-life for systemic distribution. Trades local action for prolonged activity in research applications.

A Khavinson bioregulator tripeptide designed to support pineal gland function. Studied for effects on melatonin production and circadian rhythm normalization.

An FDA-approved melanocortin receptor agonist that works in the brain to enhance sexual desire and arousal. Marketed as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.

A first-in-class triple agonist of GIP, GLP-1, and glucagon receptors showing unprecedented weight loss in clinical trials. Currently in Phase 3 development by Eli Lilly.

A synthetic anxiolytic peptide derived from tuftsin, approved in Russia for anxiety treatment. Provides anti-anxiety effects without sedation, dependence, or cognitive impairment typical of benzodiazepines.

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. One of the most effective medications for weight loss, available as once-weekly injection or daily oral tablet.

A synthetic nootropic peptide based on ACTH 4-10, approved in Russia for cognitive enhancement and stroke recovery. Known for dramatically increasing BDNF and supporting neuroplasticity.

A GHRH analog consisting of the first 29 amino acids of growth hormone-releasing hormone. Previously FDA-approved, sermorelin stimulates natural GH production while preserving physiological feedback mechanisms.

A mitochondrial-derived peptide with potent insulin-sensitizing, anti-diabetic, and neuroprotective properties that declines with age.

A unique mitochondrial-derived peptide with pro-apoptotic properties in cancer cells while protecting normal cells.

An extended 8-amino acid version of Argireline with enhanced SNARE complex inhibition. Used in cosmetics for expression line reduction.

A dual GLP-1/glucagon receptor agonist in Phase 3 trials showing up to 19% weight loss and significant MASH improvement with FDA Breakthrough Therapy designation.

A synthetic peptide mimicking snake venom component waglerin-1. Reduces expression lines by antagonizing nicotinic acetylcholine receptors.

A collagen-boosting peptide that activates the TGF-β pathway to stimulate fibroblast collagen production. Used for improving skin firmness and reducing wrinkles.

A synthetic peptide fragment derived from Thymosin Beta-4, extensively studied for tissue repair, wound healing, and cell migration. Known for its effects on actin regulation and angiogenesis.

An FDA-approved GHRH analog for treating HIV-associated lipodystrophy. Reduces excess abdominal fat by stimulating natural growth hormone release.

A triple monoamine reuptake inhibitor being developed for obesity. Inhibits serotonin, norepinephrine, and dopamine reuptake to reduce appetite and increase metabolism.

A thymic peptide complex used in Russia for immune system support. Enhances T-cell function and thymic activity, particularly in aging and immunodeficiency.

A Khavinson dipeptide bioregulator for thymus and immune system modulation, approved in Russia as an immunomodulator.

A thymic peptide approved in 35+ countries for hepatitis and immune deficiency. Enhances T-cell function and immune response. One of the most clinically validated immunomodulatory peptides.

A 43-amino acid regenerative peptide that promotes wound healing, tissue repair, and cardioprotection through actin sequestration and stem cell activation.

The first FDA-approved dual GIP/GLP-1 receptor agonist, producing record-breaking weight loss results. Approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

An FDA-approved GnRH agonist that paradoxically suppresses reproductive hormones through continuous administration. Used for prostate cancer, endometriosis, and precocious puberty.

A Khavinson bioregulator tripeptide for vascular health. Targets endothelial function and blood vessel support.

The shortest known bioactive peptide with anti-aging, immune-modulating, and chromatin-remodeling properties.

A naturally occurring 28-amino acid neuropeptide with vasodilatory, immunomodulatory, and neuroprotective functions. Studied in CIRS and inflammatory conditions.